Zhi Hong, Brii Biosciences CEO

An­oth­er Covid-19 an­ti­body cock­tail on the menu? Brii Bio touts ear­ly win in NIH study for a com­bo al­ready used in Chi­na

Months af­ter flop­ping in an NIH-spon­sored study, Brii Bio­sciences’ Covid-19 an­ti­body com­bo has re­deemed it­self in a sec­ond tri­al.

The biotech says its an­ti­bod­ies — which had hailed from Bei­jing’s Ts­inghua Uni­ver­si­ty and Shen­zhen Third Peo­ple’s Hos­pi­tal — dra­mat­i­cal­ly im­proved pa­tients’ odds of get­ting hos­pi­tal­ized or dy­ing over place­bo, notch­ing a sta­tis­ti­cal­ly sig­nif­i­cant re­duc­tion of 78%. That trans­lates to a risk ra­tio of 0.22 (95% con­fi­dence in­ter­val: 0.05, 0.86; p<.00001).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.